

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1012
(Consolidated Modification and
Enforcement Proceeding)]

Certain Magnetic Data Storage Tapes and Cartridges Containing the Same Notice of Institution of Modification Proceeding

AGENCY: U.S. International Trade
Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined to institute a modification proceeding relating to the March 8, 2018 limited exclusion order and cease and desist orders issued in the above-referenced investigation.

FOR FURTHER INFORMATION CONTACT: Megan M. Valentine, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708-2301. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-2000. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted the original investigation on July 1, 2016, based on a complaint filed by Fujifilm Corporation of Tokyo, Japan, and Fujifilm Recording Media U.S.A., Inc. of Bedford, Massachusetts (collectively, "Fujifilm"). 81 FR 43243-44 (July 1, 2016). Pertinent to this action, the complaint alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 ("section 337"), in the sale for importation, importation, and sale within the United States after importation of certain magnetic data storage tapes and cartridges containing the same by reason of infringement of, *inter alia*, claims 1, 4-9, 11 and 14 of U.S. Patent No. 6,641,891 ("the '891 patent"). The Commission's Notice of Investigation

named as respondents Sony Corporation of Tokyo, Japan, Sony Corporation of America of New York, New York, and Sony Electronics Inc. of San Diego, California (collectively, "the Sony respondents"). The Office of Unfair Import Investigations ("OUII") was also named as a party to the investigation.

On March 8, 2018, the Commission found a section 337 violation as to the '891 patent and issued a limited exclusion order ("LEO") and cease and desist orders ("CDOs") to each of the Sony respondents. 83 FR 11245-47 (March 14, 2018). The LEO generally prohibits the Sony respondents from importing certain magnetic data storage tapes and cartridges containing the same that infringe the '891 patent, with certain exceptions related to service and repair and verification testing. The CDOs prohibit the Sony respondents from importing, selling, marketing, advertising, distributing, transferring (except for exportation) certain magnetic data storage tapes and cartridges containing the same that infringe the '891 patent, and soliciting United States agents or distributors for these activities.

On May 9, 2018, Fujifilm filed a complaint requesting that the Commission institute a formal enforcement proceeding under Commission Rule 210.75 to investigate alleged violation of the CDOs by the Sony Respondents, as well as Sony Storage Media Solutions Corporation, Sony Storage Media Manufacturing Corporation, Sony DADC US Inc., and Sony Latin America Inc. (collectively, "Sony"). On June 13, 2018, the Commission instituted the enforcement proceeding. 83 FR 27626-27 (June 13, 2018). OUII was also named as a party in the enforcement proceeding.

On July 23, 2018, Sony filed a request for an advisory opinion and a petition for modification of the remedial orders to clarify that certain of its redesigned tape products are outside the scope of the remedial orders. On August 2, 2018, Fujifilm filed a response, opposing both Sony's request and petition.

Having examined the request and petition, as well as the supporting documents, the Commission has determined to institute a modification proceeding, pursuant to Commission Rule 210.76(b) (19 CFR. 210.76(b)), to determine whether the LEO and CDOs issued in the underlying investigation should be modified to exclude certain of Sony's redesigned tape products. The Commission has further determined to delegate the modification proceeding to the presiding administrative law judge and to consolidate that proceeding with the ongoing enforcement proceeding.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: August 17, 2018.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2018-18155 Filed 8-22-18; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-471P]

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2018

AGENCY: Drug Enforcement
Administration, Department of Justice.

ACTION: Notice with request for
comments.

SUMMARY: The Drug Enforcement Administration (DEA) proposes to adjust the 2018 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: Interested persons may file written comments on this notice in accordance with 21 CFR 1303.13(c) and 1315.13(d). Electronic comments must be submitted, and written comments must be postmarked, on or before September 24, 2018. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.

Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised. In the event the Administrator decides in his sole discretion to hold such a hearing, the Administrator will publish a notice of any such hearing in the **Federal Register**. After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will publish in the **Federal Register** a final order establishing the 2018 adjusted aggregate

production quotas for schedule I and II controlled substances, and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

ADDRESSES: To ensure proper handling of comments, please reference “Docket No. DEA–471P” on all correspondence, including any attachments. The Drug Enforcement Administration encourages that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <http://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on [regulations.gov](http://www.regulations.gov). If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. Paper comments that duplicate electronic submissions are not necessary and are discouraged. Should you wish to mail a paper comment *in lieu* of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT: Thomas D. Sonnen, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152, Telephone: (202) 598–6812.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received in response to this docket are considered part of the public record. They will, unless reasonable cause is given, be made available by the Drug Enforcement Administration (DEA) for public inspection online at <http://www.regulations.gov>. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

The Freedom of Information Act (FOIA) applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the

phrase “PERSONAL IDENTIFYING INFORMATION” in the first paragraph of your comment. You must also place all the personal identifying information you do not want made publicly available in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment.

Comments containing personal identifying information or confidential business information identified and located as directed above will generally be made available in redacted form. If a comment contains so much confidential business information or personal identifying information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to <http://www.regulations.gov> may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential.

An electronic copy of this document is available at <http://www.regulations.gov> for easy reference.

Legal Authority and Background

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the DEA pursuant to 28 CFR 0.100.

The DEA established the 2018 aggregate production quotas for substances in schedules I and II and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine on November 8, 2017 (82 FR 51873). That notice stipulated that, in accordance with 21 CFR 1303.13 and 1315.13, all aggregate production quotas and assessments of annual need are subject to adjustment.

Analysis for Proposed Adjusted 2018 Aggregate Production Quotas and Assessment of Annual Needs

The DEA proposes to adjust the established 2018 aggregate production quotas and assessment of annual needs for certain schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured in the United States in 2018 to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

In determining the proposed adjustment, the Acting Administrator has taken into account the criteria in accordance with 21 CFR 1303.13 (adjustment of aggregate production quotas for controlled substances) and 21 CFR 1315.13 (adjustment of the assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine). The DEA determined whether to propose an adjustment of the aggregate production quotas and assessment of annual needs for 2018 by considering: (1) Changes in the demand for that class or chemical, changes in the national rate of net disposal of the class or chemical, and changes in the rate of net disposal of the class or chemical by registrants holding individual manufacturing quotas for the class; (2) whether any increased demand for that class or chemical, the national and/or individual rates of net disposal of that class or chemical are temporary, short term, or long term; (3) whether any increased demand for that class or chemical can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota; (4) whether any decreased demand for that class or chemical will result in excessive inventory accumulation by all persons registered to handle that class or chemical; and (5) other factors affecting medical, scientific, research, and industrial needs in the United States and lawful export requirements, as the Acting Administrator finds relevant. These quotas do not include imports of controlled substances for use in industrial processes.

The Acting Administrator also considered updated information obtained from 2017 year-end inventories, 2017 disposition data submitted by quota applicants,

estimates of the medical needs of the United States, product development, and other information made available to the DEA after the initial aggregate production quotas and assessment of annual needs had been established. Other factors the Acting Administrator considered in calculating the aggregate production quotas, but not the assessment of annual needs, include product development requirements of

both bulk and finished dosage form manufacturers, and other pertinent information. In determining the proposed adjusted 2018 assessment of annual needs, the DEA used the calculation methodology previously described in the 2010 and 2011 established assessment of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20, 2010, respectively).

The Acting Administrator, therefore, proposes to adjust the 2018 aggregate production quotas for certain schedule I and II controlled substances and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class	Established 2018 quotas (g)	Proposed revised 2018 quotas (g)
Temporarily Scheduled Substances		
1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide	N/A	25.
1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide	N/A	25.
Cyclopropyl Fentanyl	N/A	20.
Fentanyl related substances	N/A	25.
Isobutyryl Fentanyl	N/A	25.
Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate	N/A	25.
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide	N/A	25.
Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	N/A	25.
Ocfentanil	N/A	25.
Para-flourobutyryl fentanyl	N/A	25.
Tetrahydrofuranlyl fentanyl	N/A	5.
Valeryl fentanyl	N/A	25.
Schedule I		
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	Zero	20.
1-(1-Phenylcyclohexyl)pyrrolidine	10	15.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	zero	10.
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	30	no change.
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)	30	no change.
1-[1-(2-Thienyl)cyclohexyl]piperidine	15	no change.
1-Benzylpiperazine	25	no change.
1-Methyl-4-phenyl-4-propionoxypiperidine	2	10.
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)	30	no change.
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)	30	no change.
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)	30	no change.
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)	30	no change.
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)	30	no change.
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)	30	no change.
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)	30	no change.
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)	25	no change.
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)	30	no change.
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)	30	no change.
2,5-Dimethoxy-4-ethylamphetamine (DOET)	25	no change.
2,5-Dimethoxy-4-n-propylthiophenethylamine	25	no change.
2,5-Dimethoxyamphetamine	25	no change.
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)	30	no change.
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)	30	no change.
3,4,5-Trimethoxyamphetamine	30	no change.
3,4-Methylenedioxyamphetamine (MDA)	55	no change.
3,4-Methylenedioxymethamphetamine (MDMA)	50	no change.
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	40	no change.
3,4-Methylenedioxy-N-methylcathinone (methylone)	40	no change.
3,4-Methylenedioxypropylvalerone (MDPV)	35	no change.
3-FMC; 3-Fluoro-N-methylcathinone	25	no change.
3-Methylfentanyl	30	no change.
3-Methylthiofentanyl	30	no change.
4-Bromo-2,5-dimethoxyamphetamine (DOB)	30	no change.
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)	25	no change.
4-Fluoroisobutyryl fentanyl	30	no change.
4-FMC; Flephedrone	25	no change.
4-MEC; 4-Methyl-N-ethylcathinone	25	no change.
4-Methoxyamphetamine	150	no change.
4-Methyl-2,5-dimethoxyamphetamine (DOM)	25	no change.
4-Methylaminorex	25	no change.

Basic class	Established 2018 quotas (g)	Proposed revised 2018 quotas (g)
4-Methyl-N-methylcathinone (mephedrone)	45	no change.
4-Methyl- α -pyrrolidinopropiophenone (4-MePPP)	25	no change.
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	50	no change.
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)	40	no change.
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	30	no change.
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate)	30	no change.
5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)	30	no change.
5-Fluoro-PB-22; 5F-PB-22	20	no change.
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone)	25	no change.
5-Methoxy-3,4-methylenedioxyamphetamine	25	no change.
5-Methoxy-N,N-diisopropyltryptamine	25	no change.
5-Methoxy-N,N-dimethyltryptamine	25	no change.
AB-CHMINACA	30	no change.
AB-FUBINACA	50	no change.
AB-PINACA	30	no change.
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	30	no change.
Acetyl Fentanyl	100	no change.
Acetyl- α -methylfentanyl	30	no change.
Acetyldihydrocodeine	30	no change.
Acetylmethadol	2	no change.
Acryl Fentanyl	25	no change.
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	50	no change.
AH-7921	30	no change.
Allylprodine	2	no change.
Alphacetylmethadol	2	no change.
α -Ethyltryptamine	25	no change.
Alphameprodine	2	no change.
Alphamethadol	2	no change.
α -Methylfentanyl	30	no change.
α -Methylthiofentanyl	30	no change.
α -Methyltryptamine (AMT)	25	no change.
α -Pyrrolidinobutiophenone (α -PBP)	25	no change.
α -Pyrrolidinopentiophenone (α -PVP)	25	no change.
Aminorex	25	no change.
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide)	25	no change.
Benzylmorphine	30	no change.
Betacetylmethadol	2	no change.
β -Hydroxy-3-methylfentanyl	30	no change.
β -Hydroxyfentanyl	30	no change.
β -Hydroxythiofentanyl	30	no change.
Betameprodine	2	no change.
Betamethadol	4	no change.
Betaprodine	2	no change.
Bufotenine	3	no change.
Butylone	25	no change.
Butyryl fentanyl	30	no change.
Cathinone	24	no change.
Codeine methylbromide	30	no change.
Codeine-N-oxide	192	no change.
Desomorphine	25	no change.
Diapromide	Zero	20.
Diethylthiambutene	Zero	20.
Diethyltryptamine	25	no change.
Difenoxin	8,225	no change.
Dihydromorphine	1,000,160	no change.
Dimethyltryptamine	35	50.
Dipipanone	5	no change.
Etorphine	30	no change.
Fenethylline	30	no change.
Furanyl fentanyl	30	no change.
γ -Hydroxybutyric acid	37,130,000	no change.
Heroin	45	no change.
Hydromorphenol	40	no change.
Hydroxypethidine	2	no change.
Ibogaine	30	no change.
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)	35	no change.
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)	45	no change.
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)	45	no change.
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)	30	no change.
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)	30	no change.

Basic class	Established 2018 quotas (g)	Proposed revised 2018 quotas (g)
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)	35	no change.
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)	30	no change.
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)	30	no change.
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)	30	no change.
Lysergic acid diethylamide (LSD)	40	no change.
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide).	30	no change.
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate).	30	no change.
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	30	no change.
Marihuana	443,680	1,140,216.
Mecloqualone	30	no change.
Mescaline	25	no change.
Methaqualone	60	no change.
Methcathinone	25	no change.
Methyldesorphine	5	no change.
Methyldihydromorphine	2	no change.
Morphine methylbromide	5	no change.
Morphine methylsulfonate	5	no change.
Morphine-N-oxide	150	no change.
N,N-Dimethylamphetamine	25	no change.
Naphyrone	25	no change.
N-Ethyl-1-phenylcyclohexylamine	5	no change.
N-Ethyl-3-piperidyl benzilate	Zero	10.
N-Ethylamphetamine	24	no change.
N-Hydroxy-3,4-methylenedioxyamphetamine	24	no change.
Noracymethadol	2	no change.
Norlevorphanol	55	no change.
Normethadone	2	no change.
Normorphine	40	no change.
Para-fluorofentanyl	25	no change.
Parahexyl	5	no change.
PB-22; QUPIC	20	no change.
Pentdrone	25	no change.
Pentylone	25	no change.
Phenomorphan	2	no change.
Pholcodine	5	no change.
Psilocybin	30	no change.
Psilocyn	50	no change.
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)	45	no change.
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)	30	no change.
Tetrahydrocannabinols	384,460	no change.
Thiofentanyl	25	no change.
THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone)	30	no change.
Tilidine	25	no change.
Trimeperidine	2	no change.
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	25	no change.
U-47700	30	no change.

Schedule II

1-Phenylcyclohexylamine	4	15.
1-Piperidinocyclohexanecarbonitrile	4	25.
4-Anilino-N-phenethyl-4-piperidine (ANPP)	1,342,320	no change.
Alfentanil	6,200	no change.
Alphaprodine	2	no change.
Amobarbital	20,100	no change.
Amphetamine (for conversion)	11,280,000	12,700,000.
Amphetamine (for sale)	39,856,000	no change.
Anileridine	Zero	20.
Carfentanil	20	no change.
Cocaine	92,120	no change.
Codeine (for conversion)	15,040,000	12,900,000.
Codeine (for sale)	40,015,000	no change.
Dextropropoxyphene	35	no change.
Dihydrocodeine	264,140	no change.
Dihydroetorphine	2	no change.
Diphenoxylate (for conversion)	14,100	no change.
Diphenoxylate (for sale)	770,800	no change.
Ecgonine	88,134	no change.
Ethylmorphine	30	no change.

Basic class	Established 2018 quotas (g)	Proposed revised 2018 quotas (g)
Etorphine hydrochloride	32	no change.
Fentanyl	1,342,320	no change.
Glutethimide	2	no change.
Hydrocodone (for conversion)	114,680	no change.
Hydrocodone (for sale)	50,348,280	44,710,000.
Hydromorphone	4,547,720	no change.
Isomethadone	30	no change.
Levo-alphaacetylmethadol (LAAM)	5	no change.
Levomethorphan	30	2,200.
Levorphanol	12,126	38,000.
Lisdexamfetamine	17,869,000	19,000,000.
Meperidine	2,717,540	1,913,148.
Meperidine Intermediate-A	5	30.
Meperidine Intermediate-B	30	no change.
Meperidine Intermediate-C	5	30.
Metazocine	15	no change.
Methadone (for sale)	22,278,000	no change.
Methadone Intermediate	24,064,000	no change.
Methamphetamine	1,446,754	no change.

[846,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for methamphetamine mostly for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)]

Methylphenidate	64,600,000	no change.
Morphine (for conversion)	4,089,000	no change.
Morphine (for sale)	33,958,440	31,456,000.
Nabilone	31,000	62,000.
Noroxymorphone (for conversion)	14,044,540	16,440,000.
Noroxymorphone (for sale)	376,000	no change.
Opium (powder)	84,600	no change.
Opium (tincture)	564,000	no change.
Oripavine	24,534,000	no change.
Oxycodone (for conversion)	2,453,400	no change.
Oxycodone (for sale)	95,692,000	85,578,000.
Oxymorphone (for conversion)	20,962,000	no change.
Oxymorphone (for sale)	3,395,280	3,137,240.
Pentobarbital	25,850,000	no change.
Phenazocine	5	no change.
Phencyclidine	35	no change.
Phenmetrazine	25	no change.
Phenylacetone	40	no change.
Racemethorphan	5	no change.
Racemorphan	5	no change.
Remifentanyl	2,820	3,000.
Secobarbital	161,682	172,100.
Sufentanyl	1,880	no change.
Tapentadol	18,388,280	no change.
Thebaine	94,000,000	86,200,000.

List I Chemicals

Ephedrine (for conversion)	47,000	no change.
Ephedrine (for sale)	4,136,000	no change.
Phenylpropanolamine (for conversion)	14,100,000	no change.
Phenylpropanolamine (for sale)	7,990,000	no change.
Pseudoephedrine (for conversion)	40	1,000.
Pseudoephedrine (for sale)	180,000,000	no change.

The Acting Administrator further proposes that aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Acting Administrator may adjust the

2018 aggregate production quotas and assessment of annual needs as needed.

Conclusion

After consideration of any comments or objections, or after a hearing, if one is held, the Acting Administrator will issue and publish in the **Federal Register** a final order establishing any adjustment of 2018 aggregate production

quotas for each basic class of controlled substances in schedules I and II and established assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 21 CFR 1303.13(c) and 1315.13(f).

Dated: August 17, 2018.
Uttam Dhillon,
Acting Administrator.
 [FR Doc. 2018–18265 Filed 8–22–18; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration

ACTION: Notice of registration.
SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement

Administration (DEA) as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR docket	Published
Fisher Clinical Services, Inc	83 FR 28663	June 20, 2018.
Unither Manufacturing LLC	83 FR 29136	June 22, 2018.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed companies.

Dated: August 17, 2018.
John J. Martin,
Assistant Administrator.
 [FR Doc. 2018–18266 Filed 8–22–18; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Greg N. Rampey, D.O.; Dismissal of Proceedings

On October 27, 2017, the Acting Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Greg N. Rampey, D.O. (Registrant), of Tulsa, Oklahoma. The Show Cause Order proposed the revocation of Registrant’s DEA Certificate of Registration No. BR7006085 on the ground that he has

“no state authority to handle controlled substances” in the State of Oklahoma, the State in which he is registered with the DEA. Order to Show Cause, Government Exhibit (GX) 2, at 1, 2 (citing 21 U.S.C. 824(a)(3)). For the same reason, the Order also proposed the denial of any of Registrant’s “applications for renewal or modification of such registration and any applications for any other DEA registrations.” *Id.* at 1.

With respect to the Agency’s jurisdiction, the Show Cause Order alleged that Registrant is the holder of Certificate of Registration No. BR7006085, pursuant to which he is authorized to dispense controlled substances as a practitioner in schedules II through V, at the registered address of 8596 E. 101st, Ste. B, Tulsa, Oklahoma. *Id.* The Order also alleged that this registration does not expire until April 30, 2018. *Id.*

As the substantive ground for the proceeding, the Show Cause Order alleged that “on September 21, 2017, the Oklahoma State Board of Osteopathic Examiners cancelled [Registrant’s] osteopathic medical license” and his “Oklahoma Bureau of Narcotics and Dangerous Drugs registration is inactive.” *Id.* at 1–2. The Show Cause Order thus alleged that Registrant is “currently without authority to practice medicine or handle controlled substances in the State of Oklahoma, the [S]tate in which [he is] registered with the DEA,” and that, as a consequence, “DEA must revoke” his registration. *Id.* at 2.

The Show Cause Order notified Registrant of (1) his right to request a hearing on the allegations or to submit a written statement in lieu of a hearing, (2) the procedure for electing either option, and (3) the consequence for failing to elect either option. *Id.* (citing 21 CFR 1301.43). The Order also

notified Registrant of his right to submit a corrective action plan. *Id.* at 2–3 (citing 21 U.S.C. 824(c)(2)(C)).

According to an Affidavit of Service filed in this matter, on October 30, 2017, personnel from DEA’s Office of Chief Counsel, Diversion and Regulatory Litigation Section, attempted to serve the Show Cause Order on the Registrant by regular first class mail addressed to the Registrant at his registered address. GX 6. The Government represents that its mailing was not returned as undeliverable. *Id.* On January 10, 2018, the Government submitted a Request for Final Agency Action (RFAA) representing that Registrant did not request a hearing and “ha[d] not filed any written statement in lieu of a hearing” within 30 days of service and seeking a final order revoking his registration. GX 7, at 2.

On February 6, 2018, the then-Acting Administrator issued an Order noting that the Government’s effort at service in this case was “a departure from the Agency’s traditional practice.” GX 8. The Order further noted that “the Government cites to no authority establishing that a sole effort of mailing by first class mail (with no evidence of delivery to the address) is sufficient to provide constitutionally adequate service for initiating a proceeding under the Due Process Clause.” *Id.* As a result, the then-Acting Administrator directed the Government to either address why its effort was consistent with the Due Process Clause or to engage in additional reasonable efforts to serve Registrant. *Id.*

On March 29, 2018, my office received the Government’s Second Request for Final Agency Action (SRFAA) describing a Diversion Investigator’s additional attempts to serve the Show Cause Order and again seeking a final order revoking Registrant’s registration. SRFAA, at 2.